Move aims to cut risk of serious side effects, including breathing problems Related items from OnMedica Tougher restrictions on valproates Long-term risk of paracetamol is underestimated Avoiding pitfalls when prescribing for children Regulator launches new corticosteroids safety module US doctor says FDA should have withdrawn rosuvastatin |
No comments:
Post a Comment